B+
Bull case
15%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-05-30 · RankAlpha Sentiment Codex
ENSC
Ensysce BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexB
Base case
40%
Probability
Target price
$0.18
Analysis reference price unavailable
Analysis 2026-05-30 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
45%
Probability
Target price
$0.05
Analysis reference price unavailable
Analysis 2026-05-30 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-30
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Primary-source tone turned more negative after the May 22 8-K because listing compliance is now an immediate process with a July 6 plan deadline, while the May 15 10-Q confirms very limited cash and ongoing dilution risk. Coverage is still thin, there is no usable analyst-revision or social-context signal, and the stock remains a binary microcap tied to funding and clinical timing rather than durable fundamentals.
RankAlpha Sentiment Codex - 2026-05-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-06catalystNasdaq equity shortfall enters a formal plan windowHigh impact
On May 21, 2026 Nasdaq notified ENSC that it was below the $2.5 million stockholders' equity requirement; the company must submit a compliance plan by July 6, 2026, and rejection of that plan or failure to regain compliance would keep delisting risk front and center [#8-K-2026-05-22].
2026-08-31eventPF614-301 enrollment is still the main clinical upside hookHigh impact
PF614-301 remains the main asset-level upside hook: the 10-K says the pivotal Phase 3 trial started in July 2025 and enrollment began in December 2025, so any enrollment update or interim-development milestone over the next few months could drive a sharp re-rating [#10-K-2026-03-30].
2026-09-30catalystCash runway remains tight and financing likelyHigh impact
Runway and dilution remain the structural long-term issue: the 10-Q shows cash and cash equivalents fell to $745,482 at March 31, 2026 from $4.31 million at year-end 2025, says cash funds operations only into late Q2 2026, and warns future viability depends on additional capital [#10-Q-2026-05-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-30 • Updated nightlySource: Internal modelMethodology